CLDN3 and prostate carcinoma: These findings strongly suggest that epigenetic silencing of claudin-3 is a common occurrence in CRPC, potentially serving as a valuable molecular marker for predicting the prognosis of prostate cancer patients and differentiating aggressive from indolent prostate tumors.